You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

ESTRADIOL AND NORETHINDRONE ACETATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Estradiol And Norethindrone Acetate patents expire, and when can generic versions of Estradiol And Norethindrone Acetate launch?

Estradiol And Norethindrone Acetate is a drug marketed by Barr, Breckenridge Pharm, Naari Pte Ltd, Novast Labs, Teva Pharms Usa, and Xiromed. and is included in six NDAs.

The generic ingredient in ESTRADIOL AND NORETHINDRONE ACETATE is estradiol; norethindrone acetate. There are seventy-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the estradiol; norethindrone acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Estradiol And Norethindrone Acetate

A generic version of ESTRADIOL AND NORETHINDRONE ACETATE was approved as estradiol; norethindrone acetate by BRECKENRIDGE PHARM on April 17th, 2008.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ESTRADIOL AND NORETHINDRONE ACETATE?
  • What are the global sales for ESTRADIOL AND NORETHINDRONE ACETATE?
  • What is Average Wholesale Price for ESTRADIOL AND NORETHINDRONE ACETATE?
Summary for ESTRADIOL AND NORETHINDRONE ACETATE
Drug patent expirations by year for ESTRADIOL AND NORETHINDRONE ACETATE
Recent Clinical Trials for ESTRADIOL AND NORETHINDRONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bio Genuine (Shanghai) Biotech Co., Ltd.Phase 3
Myovant Sciences GmbHPhase 4
University of ChicagoPhase 4

See all ESTRADIOL AND NORETHINDRONE ACETATE clinical trials

Pharmacology for ESTRADIOL AND NORETHINDRONE ACETATE
Drug ClassEstrogen
Progestin
Mechanism of ActionEstrogen Receptor Agonists

US Patents and Regulatory Information for ESTRADIOL AND NORETHINDRONE ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Barr ESTRADIOL AND NORETHINDRONE ACETATE estradiol; norethindrone acetate TABLET;ORAL 079193-001 May 11, 2010 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Pharms Usa ESTRADIOL AND NORETHINDRONE ACETATE estradiol; norethindrone acetate TABLET;ORAL 200747-001 Mar 8, 2012 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Naari Pte Ltd ESTRADIOL AND NORETHINDRONE ACETATE estradiol; norethindrone acetate TABLET;ORAL 210233-001 Feb 28, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Xiromed ESTRADIOL AND NORETHINDRONE ACETATE estradiol; norethindrone acetate TABLET;ORAL 207261-001 Feb 10, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.